专利检索 ap:("Darya ALIZADEH" OR "Christine BROWN" OR "Stephen J. FORMAN" OR "City of Hope") AND inv:"Christine E. Brown" 第 1 页

1.

发明申请
METHODS FOR MANUFACTURING T CELLS EXPRESSING OF CHIMERIC ANTIGEN RECEPTORS AND OTHER RECEPTORS 审中-公开

公开(公告)号：US20200095547A1

公开(公告)日：2020-03-26

申请号：US16465847

申请日：2017-12-01

申请人： Darya ALIZADEH , Christine BROWN , Stephen J. FORMAN , City of Hope

发明人： Darya Alizadeh , Christine E. Brown , Stephen J. Forman

IPC分类号： C12N5/0783

摘要： A method for preparing T cell populations for use in CAR T cell therapy and other immune cell therapies is described.

2.

发明申请
CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE 有权

公开(公告)号：US20220372164A1

公开(公告)日：2022-11-24

申请号：US17510099

申请日：2021-10-25

申请人： City of Hope

发明人： Stephen J. Forman , Christine E. Brown , Uma Maheswara Rao Jonnalagadda , Armen Mardiros

IPC分类号： C07K16/30 , C07K14/725 , C07K14/705 , C07K16/28 , C07K14/71 , C07K16/00 , A61K39/395 , A61K45/06

摘要： Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

3.

发明申请
CD6 TARGETED CHIMERIC ANTIGEN RECEPTORS FOR TREATENT OF CERTAIN AUTOIMMUNE DISORDERS 有权

公开(公告)号：US20210395329A1

公开(公告)日：2021-12-23

申请号：US17256788

申请日：2019-07-01

申请人： City of Hope

发明人： Jose Enrique Montero Casimiro , Bart Otto Roep , Christine E. Brown

IPC分类号： C07K14/725 , C07K16/28 , C07K14/705 , C07K14/73 , A61K35/17

摘要： Provided herein are, inter alia, CD6 targeting CAR-T cell compositions and methods useful for treating autoimmune diseases (e.g., Type I diabetes).

4.

发明申请
CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE 审中-公开

公开(公告)号：US20200040096A1

公开(公告)日：2020-02-06

申请号：US16221257

申请日：2018-12-14

申请人： City of Hope

发明人： Stephen J. Forman , Christine E. Brown , Uma Maheswara Rao Jonnalagadda , Armen Mardiros

IPC分类号： C07K16/30 , C07K14/705 , A61K45/06 , A61K39/395 , C07K16/28 , C07K14/725 , C07K16/00 , C07K14/71

摘要： Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

5.

发明申请
CHIMERIC ANTIGEN RECEPTORS CONTAINING A CHLOROTOXIN DOMAIN 审中-公开

公开(公告)号：US20190389917A1

公开(公告)日：2019-12-26

申请号：US15767960

申请日：2016-10-13

申请人： City of Hope

发明人： Michael Barish , Christine E. Brown , Stephen J. Forman , Dongrui Wang

IPC分类号： C07K14/435 , C07K14/73 , C07K14/705 , C07K14/725 , A61K35/17 , A61P35/00 , C12N5/0783

摘要： Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes chlorotoxin or a related toxin, or a variant of chlorotoxin or a related toxin, that binds to human glioma or other human tumor cells, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.

6.

发明授权
Costimulatory chimeric antigen receptor T cells targeting IL13Rα2 有权

公开(公告)号：US09914909B2

公开(公告)日：2018-03-13

申请号：US15167869

申请日：2016-05-27

申请人： City of Hope

发明人： Christine E. Brown , Stephen J. Forman

IPC分类号： C12N5/0783 , C07K14/54 , C07K14/715 , A61K35/17 , C07K14/725 , C07K14/73 , C07K14/705 , A61K38/00

CPC分类号： C12N5/0636 , A61K35/17 , A61K38/00 , C07K14/5437 , C07K14/7051 , C07K14/70514 , C07K14/70578 , C07K14/7155 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/74 , C07K2319/75 , C12N2510/00 , C12N2740/16043

摘要： Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes IL-13 or a variant thereof that binds interleukin-13Rα2 (IL13Rα2), a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.

7.

发明申请
Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System 审中-公开

公开(公告)号：US20170224733A1

公开(公告)日：2017-08-10

申请号：US15425773

申请日：2017-02-06

申请人： City of Hope

发明人： Behnam Badie , Christine E. Brown , Stephen J. Forman , Saul J. Priceman

IPC分类号： A61K35/17 , A61K38/20 , A61K38/17 , A61K9/00

摘要： An improved method of treating cancers with engineered T cells is described.

8.

发明申请
METHODS OF MAKING AND USING REGULATORY T CELLS AND EFFECTOR T CELLS HAVING CHIMERIC ANTIGEN RECEPTORS TARGETED TO CD6, CD19, AND/OR AN IL-13R FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS 有权

公开(公告)号：US20230076643A1

公开(公告)日：2023-03-09

申请号：US17789930

申请日：2020-12-30

申请人： CITY OF HOPE

发明人： Jose Enrique Montero Casimiro , Bart Otto Roep , Christine E. Brown

IPC分类号： C07K16/28 , C12N15/86 , A61K35/17 , C07K16/24 , A61P35/00

摘要： Provided herein are, inter alia, CAR-T cell compositions targeting CD6, CD19, and/or an IL-13R, and methods useful for treating autoimmune diseases and cancer.

9.

发明申请
METHODS FOR MANUFACTURING T CELLS EXPRESSING OF CHIMERIC ANTIGEN RECEPTORS AND OTHER RECEPTORS 有权

公开(公告)号：US20220145252A1

公开(公告)日：2022-05-12

申请号：US17599786

申请日：2020-03-30

申请人： City of Hope

发明人： Christine E. Brown , Dongrui Wang , Stephen J. Forman

IPC分类号： C12N5/0783

摘要： A method for manufacturing T cell populations enriched for cells expressing CD27 and useful in T cell therapy is described. The T cell populations are also useful for a variety of purposes requiring a highly active, long-lived T cell population. Such cells elicit a superior antitumor immune response in vitro and in vivo.

10.

发明申请
COMBINATION THERAPY COMPRISING CANCER-TARGETED CAR-T CELLS AND A METHOD OF USING SAME FOR A TREATMENT FOR CANCER 有权

公开(公告)号：US20220072043A1

公开(公告)日：2022-03-10

申请号：US17470843

申请日：2021-09-09

申请人： Mustang Bio, Inc , Beckman Research Institute of the City of Hope

发明人： Knut Niss , Sadik H. Kassim , Christine E. Brown , Stephen J. Forman , Behnam Badie

IPC分类号： A61K35/17 , C07K14/725 , C07K14/705 , C07K14/73 , C07K14/71 , C07K16/28 , C07K16/32 , A61K35/763

摘要： Described are improved methods for treating solid tumors, such as malignant gliomas, with a dual approach utilizing a CAR-T immunotherapy and a viral oncolytic therapy.